Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. It is an oral, selective ACTH antagonist.
Atumelnant is now in Phase 2 of development and you can read the latest research results at the link below:
Once Daily Oral Atumelnant (CRN04894) Induces Rapid and Profound Reductions of Androstenedione and 17-hydroxyprogesterone in Participants with Classical Congenital Adrenal Hyperplasia: Initial Results From a12-Week, Phase 2, Open-Label Study
Richard J. Auchus, MD, PhD, Peter J. Trainer, MD, Kathryn Jean Lucas, MD3, et al
Poster: Annual Meeting of the Endocrine Society (ENDO); 6/03/2024
Click here to read more about Alumelnant on Crinetics’ website.
Recent Blog Posts
New report highlights access gap for innovative medicines
The CAH Support Group recently provided input into a new Medicines Australia report about access to innovative medicines in Australia. The report, now published, warns that Australian patients are missing access to some innovative medicines available in comparable...
Help Shape New UK Sick Day Guidance for Young People with Adrenal Insufficiency
Young people with adrenal insufficiency (including CAH and Addison's disease) and parents/carers are being invited to help shape new UK-wide resources on sick day rules and emergency management. The project is being led by Edge Hill University in partnership with the...
Article: Adult Quality of Life with CAH
A new study published in Endocrine Connections explores the lived experiences of adults with congenital adrenal hyperplasia (CAH) and the wide-ranging impact the condition can have on quality of life. Through in-depth interviews with adults living with CAH as well as...